These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29669391)

  • 1. Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis.
    Kjelgaard-Petersen CF; Platt A; Braddock M; Jenkins MA; Musa K; Graham E; Gantzel T; Slynn G; Weinblatt ME; Karsdal MA; Thudium CS; Bay-Jensen AC
    Arthritis Rheumatol; 2018 Sep; 70(9):1419-1428. PubMed ID: 29669391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
    Scott DL
    Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
    Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
    J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase-dependent turnover of cartilage, synovial membrane, and connective tissue is elevated in rats with collagen induced arthritis.
    Siebuhr AS; Wang J; Karsdal M; Bay-Jensen AC; Y J; Q Z
    J Transl Med; 2012 Sep; 10():195. PubMed ID: 22992383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients.
    Gudmann NS; Hirata S; Karsdal MA; Kubo S; Bay-Jensen AC; Tanaka Y
    Clin Exp Rheumatol; 2018; 36(3):462-470. PubMed ID: 29465351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
    Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
    J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.
    Connolly M; Mullan RH; McCormick J; Matthews C; Sullivan O; Kennedy A; FitzGerald O; Poole AR; Bresnihan B; Veale DJ; Fearon U
    Arthritis Rheum; 2012 Apr; 64(4):1035-45. PubMed ID: 22076945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neo-Epitopes--Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis.
    Maijer KI; Gudmann NS; Karsdal MA; Gerlag DM; Tak PP; Bay-Jensen AC
    PLoS One; 2016; 11(3):e0149329. PubMed ID: 27019199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis.
    Bay-Jensen AC; Wichuk S; Byrjalsen I; Leeming DJ; Morency N; Christiansen C; Karsdal MA; Maksymowych WP
    PLoS One; 2013; 8(1):e54504. PubMed ID: 23365672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.
    Taylor PC; Genovese MC; Greenwood M; Ho M; Nasonov E; Oemar B; Stoilov R; Vencovsky J; Weinblatt M
    Ann Rheum Dis; 2015 Dec; 74(12):2123-9. PubMed ID: 25074688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.
    Gudmann NS; Junker P; Juhl P; Thudium CS; Siebuhr AS; Byrjalsen I; Karsdal MA; Bay-Jensen AC
    Clin Exp Rheumatol; 2018; 36(5):829-835. PubMed ID: 29745884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of pathological RA endotypes using blood-based biomarkers reflecting tissue metabolism. A retrospective and explorative analysis of two phase III RA studies.
    Blair JPM; Bager C; Platt A; Karsdal M; Bay-Jensen AC
    PLoS One; 2019; 14(7):e0219980. PubMed ID: 31339920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
    Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
    Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
    Scott IC; Scott DL
    Drugs; 2014 Mar; 74(4):415-22. PubMed ID: 24610702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
    Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME
    J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
    Thudium CS; Bay-Jensen AC; Cahya S; Dow ER; Karsdal MA; Koch AE; Zhang W; Benschop RJ
    Arthritis Res Ther; 2020 Oct; 22(1):235. PubMed ID: 33046136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
    Kitas GD; Abreu G; Jedrychowicz-Rosiak K; Miller JL; Nakov R; Panfilov S; Vencovsky J; Wang M; Weinblatt ME; White WB
    J Am Soc Hypertens; 2014 Nov; 8(11):780-90. PubMed ID: 25455003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.